Promoted Content
Promoted Content

Find Drugs for Cardiology/Vascular Diseases in Phase I Clinical Development

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ASC41

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: ASC41

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 22, 2020

            Details:

            The trial aims to evaluate 1) the impact of ASC41 on markers of cardiac health; 2) the safety and tolerability of ASC41 tablets; 3) the pharmacokinetics of ASC41 tablets and its active moiety, ASC41-A, in overweight and obese subjects.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): DTRI-031

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: DTRI-031

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Rev1 Ventures

            Deal Size: $5.4 million Upfront Cash: Undisclosed

            Deal Type: Financing December 07, 2020

            Details:

            The Company’s development candidate, DTRI-031, is an RNA aptamer that inhibits von Willebrand Factor (vWF). Basking is co-developing a matched oligonucleotide reversal agent, DTRI-025, for as-needed, rapid reversal of DTRI-031.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): SEFA-1024

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: SEFA-1024

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 20, 2020

            Details:

            SEFA-1024 is a novel chemically modified fatty acid derived from naturally occurring fatty acid EPA. Phase 1 trial will evaluate the safety, tolerability, and pharmacokinetics of SEFA-1024 in 96 otherwise healthy volunteers with high plasma triglyceride levels.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): SLN360

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: SLN360

            Highest Development Status: Phase I Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 16, 2020

            Details:

            Results presented show that the distribution of SLN360 is confined to the liver (target organ) and kidney (route of elimination) as intended, with levels of SLN360 in other organs (including reproductive organs) less than 1% of peak liver levels.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ARO-ANG3

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: ARO-ANG3

            Highest Development Status: Phase I Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 13, 2020

            Details:

            Arrowhead Pharmaceuticals to present positive clinical data from multiple product candidates in its cardiometabolic pipeline which includes ARO-APOC3, ARO-ANG3 and AMG 890.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ALN-AGT

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: ALN-AGT

            Highest Development Status: Phase I Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 13, 2020

            Details:

            Patients receiving investigational ALN-AGT experienced dose-dependent reductions in blood pressure, confirming potential for rnai-mediated angiotensinogen (AGT) silencing as a novel therapeutic approach for hypertension.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CDR132L

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: CDR132L

            Highest Development Status: Phase I Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 22, 2020

            Details:

            The study demonstrates that repeated treatment with its lead compound Cdr132 L is safe, improves cardiac function and reduces both ventricular as well as left atrial volumes in chronic heart failure.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CK-3772271

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: CK-271

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 23, 2020

            Details:

            CK-271 is a second cardiac myosin inhibitor, discovered by company scientists, in development for the potential treatment of hypertrophic cardiomyopathy (HCM).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): JK07

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: JK07

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Carlyle

            Deal Size: $260.0 million Upfront Cash: Undisclosed

            Deal Type: Acquisition September 01, 2020

            Details:

            Salubris has developed a comprehensive innovative pipeline in the treatment of chronic diseases, including JK07, an innovative biologic drug treating heart failure which has filed for clinical trial approvals in both China and the United States.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ARO-APOC3

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: ARO-APOC3

            Highest Development Status: Phase I Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 31, 2020

            Details:

            Presentation to showcase Phase 1/2 clinical data on two RNAi-based cardiometabolic candidates, ARO-APOC3 targeting apolipoprotein C-III being developed as a treatment for patients with hypertriglyceridemia, and ARO-ANG3 being developed as a treatment for mixed dyslipidemias.